

## Cleansing notice under Section 708A (5)(e) of the Corporations Act

This notice is given by **Rhythm Biosciences Limited (ASX: RHY) (Rhythm or the Company)** under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (the Corporations Act).

<b>Type</b>	Shares
<b>Class/description</b>	Ordinary
<b>ASX code</b>	RHY
<b>Date of issue</b>	15 April 2026
<b>Number issued</b>	18,834,007

The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act that:

1. the Company issued the Shares without disclosure under Part 6D.2 of the Corporations Act;
2. as at the date of this notice, the Company has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (ii) sections 674 and 674A of the Corporations Act; and
3. as at the date of this notice, there is no information to be disclosed which is 'excluded information' (as defined in sections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by the Company.

- ENDS -

**This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.**

**For further information contact us via [investors@rhythmbio.com](mailto:investors@rhythmbio.com).**

### About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and X.

### About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet relevant regulatory standards.

**Rhythm Biosciences Ltd**  
ACN 619 459 335  
ASX: RHY

**Australian Registered Address**  
Bio21 Molecular Science & Biotechnology Institute  
30 Flemington Road  
Parkville VIC 3010 Australia

### Directors

Gavin Fox-Smith	Non-Executive Chairman
Sue MacLeman	Non-Executive Director
David Atkins	CEO & Managing Director

[www.rhythmbio.com](http://www.rhythmbio.com)

T +61 3 8256 2880  
E [investors@rhythmbio.com](mailto:investors@rhythmbio.com)

The ColoSTAT<sup>®</sup> Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

**About geneType<sup>™</sup>**

geneType<sup>™</sup> is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit [www.genetype.com](http://www.genetype.com).